QuickView for complement component C3b binding (biogroup)

1. Breast cancer cells co-cultured with fibroblasts expression profile
2. NSCLC PC9 cells selected for gefitinib sensitivity or resistance treated with EGF and gefitinib
3. L1000 CMAP - Neural progenitor NPC cells treated with small molecule perturbagens
4. L1000 CMAP - Skeletal muscle SKL.C cells treated with small molecule perturbagens
5. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)

There were no matches for complement component C3b binding

1. First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers
2. Effects of Multiple Concussions in Retired NHL Players
3. Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
4. First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers